SG/CALL/VERTEX PHARMACEUTICALS/260/0.1/17.01.25 | Market Closed - Deutsche Boerse AG 20:39:10 03/07/2024 BST | ||
| 20.06 EUR | -3.51% |
|
| Current month | +1.22% | ||
| 1 month | +8.91% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 20.06 | -3.51% |
| 02/07/24 | 20.79 | +0.82% |
| 01/07/24 | 20.62 | +0.39% |
| 28/06/24 | 20.54 | -1.68% |
| 27/06/24 | 20.89 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update July 03, 2024 at 08:39 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SQ864R |
| ISIN | DE000SQ864R4 |
| Date issued | 16/02/2023 |
| Strike | 260 $ |
| Maturity | 17/01/2025 (198 Days) |
| Parity | 10 : 1 |
| Emission price | 8.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.85 € |
|---|---|
| Lowest since issue | 7.26 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.3
USD
Average target price
468.3
USD
Spread / Average Target
-0.43%
- Stock Market
- Warrants
- Warrant
